Business context and reporting period
Entity note: The supplied filing is Salarius Pharmaceuticals, Inc.’s Form 10-K, not a filing for Decoy Therapeutics Inc. It covers the fiscal year ended December 31, 2020, and was filed March 18, 2021. The company is a clinical-stage biotechnology business developing seclidemstat (SP-2577), an LSD1 inhibitor, for Ewing sarcoma, related sarcomas and advanced solid tumors. It has no approved products and no product-sale revenue. Following its 2019 merger, the financial statements reflect Private Salarius as the accounting acquirer.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Grant revenue | $5.23 million | $3.47 million |
| Research and development expense | $6.91 million | $4.02 million |
| General and administrative expense | $6.11 million | $7.71 million |
| Net loss | $7.35 million | $6.94 million |
| Net cash used in operating activities | $10.31 million | $11.58 million |
| Cash and cash equivalents at year-end | $11.12 million | $3.74 million |
Grant revenue was entirely from CPRIT and is not product-sale revenue. Operating expenses totaled $13.02 million; operating margin on grant revenue is not a meaningful measure for this development-stage company. Loss per common share was $0.50 in 2020 versus $2.12 in 2019; weighted-average shares increased to 15.58 million from 3.27 million. The filing separately reports a $0.40 million warrant-modification charge affecting loss attributable to common stockholders.
At December 31, 2020, working capital was $13.0 million, total assets were $24.93 million, total liabilities were $2.77 million, and stockholders’ equity was $22.16 million. Current note payable was $0.48 million. Cash used in investing activities was $0.003 million; financing activities provided $17.69 million, primarily from equity issuance and warrant exercises. No off-balance-sheet arrangements were reported.
Material changes versus the prior year
- Grant revenue rose $1.77 million (about 51%), reflecting higher qualifying expenses reimbursable under the CPRIT grant.
- R&D expense increased $2.89 million (about 72%), mainly from manufacturing active pharmaceutical ingredient ahead of expected clinical activity and higher personnel and consulting costs; clinical trial spending was lower.
- G&A expense declined $1.61 million (about 21%), as lower professional and merger-related costs outweighed higher personnel and directors’ and officers’ insurance costs.
- Net loss increased by $0.42 million, while operating cash use declined by $1.27 million. Year-end cash increased by $7.38 million, mainly due to financing.
- Common shares outstanding increased substantially during 2020 through offerings and warrant exercises; the filing reports 23.81 million issued shares at year-end, versus 4.52 million in 2019.
Outlook, commentary and risks
Management expected continued significant losses and higher development spending, with no product-sale revenue expected for the foreseeable future. The company said year-end 2020 cash alone would not be sufficient for its plans, but subsequent financing alleviated substantial doubt about its ability to continue as a going concern for the 12 months from issuance. The filing estimates approximately $37 million of cash availability as of March 18, 2021, and states this should fund anticipated needs for at least 12 months from filing; additional capital may still be needed sooner or later depending on development progress and other factors.
After year-end, Salarius completed a February 2021 at-the-market offering generating approximately $6.3 million gross, received approximately $1.5 million from warrant exercises, and completed a March 8 public offering generating approximately $23 million gross ($21.1 million net). These financings dilute existing holders. CPRIT grant funding is subject to matching and other conditions; the grant contract was extended to November 30, 2021, and approximately $2.6 million associated with a discontinued prostate study is no longer available. The filing says $4.8 million remained available to draw subject to requirements.
Clinical outlook is uncertain. In early 2021, the Ewing sarcoma trial reached its recommended Phase 2 dose and was to enter dose expansion; the company planned to study SP-2577 with topotecan/cyclophosphamide in Ewing sarcoma and as a single agent in FET-translocated sarcomas. Its separate advanced solid tumor study remained in dose escalation. These are early-stage trials, and further trials would be required for approval. Fast Track and rare pediatric disease designations do not assure faster review, approval or a priority review voucher.
Key risks include clinical safety or efficacy failures, slow enrollment in rare cancers, dependence on contract manufacturers and trial vendors, ongoing financing needs, competition, patent and licensing uncertainty, and dependence on CPRIT funding. Salarius gave notice of intent to terminate its South Korean sublicense with HLB Life Sciences over alleged default; the final termination determination was pending. COVID-19 had caused minimal clinical-trial disruption and no manufacturing disruption as of the filing, but further effects remained uncertain. No material legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor issued an unmodified opinion on the financial statements but did not audit internal control effectiveness.
Most important facts for investors to verify
- Whether the stated post-financing cash runway remains adequate as clinical and manufacturing costs rise, and what assumptions underpin the at-least-12-month estimate.
- Current CPRIT draw availability, matching compliance, grant receivable collection timing, and any repayment exposure or consequences if contract requirements are not met.
- Updated trial enrollment, safety, efficacy and dose-expansion results for SP-2577, including the planned combination regimen and FET-translocated sarcoma cohort.
- Post-offering share count, outstanding warrants and potential dilution; the filing reports 44,734,328 common shares outstanding as of March 15, 2021.
- Resolution of the HLB Life Sciences sublicense default and the status of Salarius’s licensed patent protection and related obligations.